Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity

British Journal of Cancer

Volumn 74, Issue 4, 1996, Pages 508-512

  McLeod, H L ^a   Keith, W N ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Drug resistance; Fluorescence in situ hybridisation; SN38; Topoisomerase I

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; DNA TOPOISOMERASE;

ARTICLE; BREAST CANCER; COLON CANCER; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCUS; HUMAN; HUMAN CELL; ISOCHROMOSOME; POLYSOME; PRIORITY JOURNAL;

EID: 0029758307     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.394     Document Type: Article

References (23)

1. COUTTS J, PLUMB JA, BROWN F AND KEITH WN. (1993). Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes. Br. J. Cancer, 68, 793-800.
2. DEVILEE P, VAN VLIET M, VAN SLOUN P, DIJKSHOORN NK, HERMENS J, PEARSON PL AND CORNELISSE CJ. (1991). Allelotype of human breast carcinoma: a second major site for loss of heterozygosity is on chromosome 6q. Oncogene, 6, 1705-1711.
3. EPSTEIN FH. (1986). Clinical implications of tumour cell heterogeneity. N. Eng. J. Med., 314, 1423-1431.
4. HUSAIN K, MOHLER JL, SEIGLER HF AND BESTERMAN JM. (1994). Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res., 54, 539-546.
5. JUAN CC, HWANG J, LIU AA, WHANG-PENG J, KNUTSEN T, HUEBNER K, CROCE CM, ZHANG H, WANG JC AND LIU LF. (1988). Human topoisomerase I is encoded by a single copy gene that maps to chromosome region 20q12 13.2. Proc. Natl Acad. Sci. USA, 85, 8910-8913.
6. KALLIONIEMI A, KALLIONIEMI O-P, PIPER J, TANNER M, STOKKE T, CHEN L, SMITH HS, PINKEL D, GRAY JW AND WALDMAN FM. (1994). Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridisation. Proc. Natl Acad. Sci USA, 91, 2156 - 2160.
7. KEITH WN, DOUGLAS F, WISHART GC, MCCALLUM HM, GEORGE WD, KAYE SB AND BROWN R. (1993). Co-amplification of erbB2, topoisomerase IIα and retinoic acid receptor α genes in breast cancer and allelic loss at topoisomerase 1 on chromosome 20. Eur. J. Cancer, 29A, 1469 - 1475.
8. KUNZE N, YANG GC, JIANG ZY, HAMEISTER H, ADOLPH S, WIEDORN KH, RICHTER A AND KNIPPERS R. (1989). Localisation of the active type I DNA topoisomerase gene on human chromosome 20q11.2-13.1, and two pseudogenes on chromosomes 1q23 24 and 22q11.2 13.1. Hum. Genet., 84, 6-10.
9. KUNZE N, YANG G, DÖLBERG M, SUNDARP R, KNIPPERS R AND RICHTER A. (1991). Structure of the Human type I DNA topoisomerase gene. J. Biol. Chem., 266, 9610-9616.
10. LEE MP, BROWN SD, CHEN A AND HSIEH T. (1993). DNA topoisomerase I is essential in Drosophila melanogaster. Proc. Natl Acad. Sci. USA, 90, 6656 - 6660.
11. LICHTER P, TANG CC, CALL K, HERMANSON G, EVANS GA, HOUSMAN D AND WARD DC. (1990). High-resolution mapping of human chromosome 11 by in situ hybridization with cosmid clones. Science, 247, 64 - 69.
12. MCLEOD HL, DOUGLAS F, OATES M, SYMONDS RP, PRAKASH D, VAN DER ZEE AGJ, KAYE SB, BROWN R AND KEITH WN. (1994). Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int. J. Cancer, 59, 607-611.
13. MASCIO LN, VERBEEK PW, SUDAR D, KUO WI. AND GRAY JW. (1995). Semiautomated DNA probe mapping using digital imaging microscopy: I. System development. Cytometry, 19, 51-59.
14. MERTENS F, JOHANSSON B AND MITELMAN F. ISOCHROMOSOMES IN NEOPLASIA. (1994). Genes, Chromosom., Cancer, 10, 221-230.
15. MURPHY DS, MCHARDY P, COUTTS J, MALLON EA, GEORGE WD, KAYE SB, BROWN R AND KEITH WN. (1995). Interphase cytogenetic analysis of ERBB2 and TOPOII alpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int. J. Cancer, 64, 18-26.
16. PLUMB JA, MILROY R AND KAYE SB. (1989). Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res, 49, 4435-4440.
17. POMMIER Y, LETEURTRE F, FESEN MR, FUJIMORI A, BERTRAND R, SOLARY E, KOHLHAGEN G AND KOHN KW. (1994). Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest., 12: 530-542.
18. POTMESIL M. (1994). Camptothecins: from the laboratory to the bedside. Cancer Res., 54, 431-1439.
19. SAKAMOTO M, PINKEL D, MASCIO L, SUDAR D, PETERS D, KUO WL, YAMAKAWA K, NAKAMURA Y, DRABKIN H, JERICEVIC Z, SMITH L AND GRAY JW. (1995). Semiautomated DNA probe mapping using digital imaging microscopy: II. System performance. Cytometry, 19, 60-69.
20. SLICHENMYER WJ, ROWINSKY EK, DONEHOWER RC AND KAUFMANN SH. (1993). The current status of camptothecin analogues as antitumour agents. J. Natl Cancer Inst., 85, 271-291.
21. TANIZAWA A, FUJIMORI A, FUJIMORI Y AND POMMIER Y. (1994). Comparison of Topoisomerase I inhibition. DNA damage, and cytotoxcity of camptothecin derivatives presently in clinical trials. J. Natl Cancer Inst., 86, 836-842.
22. TANNER MM, TIRKKONEN M, KALLIONIEMI A, COLLINS C, STOKKE T, KARHU R, KOWBEL D, SHADRAVAN F, HINTZ M, KUO W-L, WALDMAN FM, ISOLA JJ, GRAY JW AND KALLIONIEMI O-P. (1994). Increased copy number at 20q13 in breast cancer: Defining the critical region and exclusion of candidate genes. Cancer Res, 54, 4257-4260.
23. VAN DER ZEE AGJ, HOLLEMA H, DE JONG S, BOONSTRA H, GOUW A, WILLEMSE PHB, ZIJLSTRA JG AND DE VRIES EGE. (1991). P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res., 51, 5915-5920.